David Gershenson, MD
Treatment with the MEK inhibitor trametinib (Mekinist) significantly improved progression-free survival (PFS) and led to a strong trend toward improved overall survival (OS) in recurrent, low-grade serous ovarian cancer, a randomized trial showed.
Median PFS improved from 7.2 months with current standard-of-care (SOC) options to 13.0 months with trametinib. OS increased by 8 months, but just missed achieving statistical significance (P
More than four times as many patients achieved objective responses with the MEK inhibitor, and responses last more than twice as long, as reported at the 2019 ESMO Congress.
... to read the full story